Format

Send to

Choose Destination
Endocrinol Metab (Seoul). 2016 Sep;31(3):476-479. doi: 10.3803/EnM.2016.31.3.476. Epub 2016 Jul 26.

Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis.

Author information

1
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
2
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. ldj6026@catholic.ac.kr.

Abstract

Cholestyramine (CS) is an ion exchange resin, which binds to iodothyronines and would lower serum thyroid hormone level. The use of CS added to conventional antithyroid drugs to control thyrotoxicosis has been applied since 1980's, and several studies indicate that using CS in combination with methimazole (MZ) produces a more rapid decline in serum thyroid hormones than with only MZ treatment. Our recent retrospective review of five patients taking high dose MZ and CS, compared to age-, gender-, initial free thyroxine (T4) level-, and MZ dose-matched 12 patients with MZ use only, showed more rapid decline of both free T4 and triiodothyronine levels without more adverse events. CS could be safely applicable short-term adjunctive therapy when first-line antithyroid medications are not enough to adequately control severe thyrotoxicosis or side effects of antithyroid drug would be of great concern.

KEYWORDS:

Cholestyramine resin; Graves disease; Thyrotoxicosis

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Supplemental Content

Full text links

Icon for Korean Endocrine Society Icon for PubMed Central
Loading ...
Support Center